08/15/2026
Rigel Pharmaceuticals, Inc. is conducting a study with R289, an oral IRAK ยผ inhibitor on patients who are relapsed/refractory/resistant to prior LR-MDS therapies (NCT05308264).
Participants must:
-Have definitive diagnosis of very low to immediate risk of MDS
-Be relapsed, refractory to or ineligible for ESAs and have received one or more approved therapies for LR-MDS
-Be RBC transfusion dependent, however no history of autologous/allogeneic stem cell transplantation
You will take the medication either once a day or twice a day. Every participant will receive R289. There is no placebo in this study.
Interested in Learning More? To determine eligibility visit https://bit.ly/IRAKRigel or contact the MDS Foundation:
Lisa Liskey
[email protected]